Dr. Michael Kelsh joins EpidStrategies, a Division of ToxStrategies LLC
EpidStrategies, a Division of ToxStrategies LLC, is pleased to announce the addition of Dr. Michael Kelsh to our team, adding considerable depth to… read more
Latest News
ToxStrategies scientists presenting at The Charles River Biotech Symposium
ToxStrategies scientists Marcie Wood, Ph.D. and Kirsten Mease, B.S. will be presenting at The Charles River Biotech Symposium – Biotechnology-Derived Therapeutics Perspectives on… read more
How are Decisions Made Regarding Safe Levels of Radiation in the Environment?
For more than a century, radiation health has been a concern for the public and for workers. However, the launch of the Hollywood… read more
New Infant RSV Prevention to be Available this Fall
In the United States, a new monoclonal antibody (nirsevimab; trade name: Beyfortus) was recently approved by the FDA and recommended by the CDC… read more
New Requirements under the EPA Coal Combustion Residuals Rule: Legacy and Environmental Justice
Coal Combustion Residuals (CCRs) are generated from the combustion of coal in producing steam for generation of electricity by electric utilities and independent… read more
ToxStrategies Acquires Modality Solutions
ToxStrategies LLC is excited to announce that Modality Solutions is joining forces with our firm, greatly expanding our ability to serve the evolving needs of… read more
EpidStrategies scientists present at ICPE 2023, Halifax Nova Scotia, August 23-27
EpidStrategies is excited to be attending and presenting at The International Society for Pharmacoepidemiology’s (ISPE) 39th Annual Meeting (ICPE 2023), August 23rd through… read more
Dr. Rayetta Henderson will provide witness testimony during the “Hemp in the Modern World: The Yearslong Wait for FDA Action” hearing to be held on July 27, 2023.
Dr. Rayetta Henderson will provide witness testimony during the “Hemp in the Modern World: The Yearslong Wait for FDA Action” hearing to be… read more